Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9829 in CD123-Positive Hematological Malignancies
NCT06179511Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of AZD9829 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by AstraZeneca. Started Jan 2024; status: completed.
02
Drugs
AZD9829
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06179511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179511.